![](https://thehcdata.com/wp-content/uploads/2024/03/pexels-sora-shimazaki-5668859-1.webp)
Inogen, Inc. (Nasdaq: INGN), a leading medical technology company specializing in innovative respiratory products for homecare, has appointed Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he held the same roles since 2018.
Mr. Smith brings nearly thirty years of experience to the company, having previously served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities, business development, and intellectual property. His career also includes leadership positions such as general counsel for the Danaher Life Sciences Platform and roles in senior legal positions at Novartis Pharmaceuticals. Before transitioning to in-house roles, Mr. Smith worked at multinational law firms in New York, Silicon Valley, and London.
Kevin Smith, President and Chief Executive Officer of Inogen, commented, “Kevin will be an invaluable addition to our leadership team at Inogen. His extensive experience in the medical device and securities field will play an important role in strengthening our legal team and ensuring Inogen remains an organization based on integrity and compliance.”
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a global leader in medical technology, specializing in innovative respiratory products designed for homecare use. Inogen supports patients with chronic respiratory conditions by developing, manufacturing, and marketing best-in-class portable oxygen concentrators that deliver supplemental long-term oxygen therapy. Inogen collaborates closely with patients, prescribers, home medical equipment providers, and distributors to ensure widespread availability of its oxygen therapy products, enabling patients to manage their conditions while maintaining mobility.